



Universiteit  
Leiden  
The Netherlands

## **Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter**

Andrea, C.E. de; Hogendoorn, P.C.W.

### **Citation**

Andrea, C. E. de, & Hogendoorn, P. C. W. (2012). Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. *The Journal Of Pathology*, 226(2), 219-228. doi:10.1002/path.3003

Version: Not Applicable (or Unknown)

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/99969>

**Note:** To cite this publication please use the final published version (if applicable).

# Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter

Carlos E de Andrea and Pancras CW Hogendoorn\*

Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands

\*Correspondence to: Pancras CW Hogendoorn, Department of Pathology, Leiden University Medical Centre, PO Box 9600, LI-Q, 2300 RC Leiden, The Netherlands. e-mail: P.C.W.Hogendoorn@lumc.nl

## Abstract

Chondrocytes interact with their neighbours through their cartilaginous extracellular matrix (ECM). Chondrocyte–matrix interactions compensate the lack of cell–cell contact and are modulated by proteoglycans and other molecules. The epiphyseal growth plate is a highly organized tissue responsible for long bone elongation. The growth plate is regulated by gradients of morphogens that are established by proteoglycans. Morphogens diffuse across the ECM, creating short- and long-range signalling that lead to the formation of a polarized tissue. Mutations affecting genes that modulate cell–matrix interactions are linked to several human disorders. Homozygous mutations of *EXT1/EXT2* result in reduced synthesis and shortened heparan sulphate chains on both cell surface and matrix proteoglycans. This disrupts the diffusion gradients of morphogens and signal transduction in the epiphyseal growth plate, contributing to loss of cell polarity and osteochondroma formation. Osteochondromas are cartilage-capped bony projections arising from the metaphyses of endochondral bones adjacent to the growth plate. The osteochondroma cap is formed by cells with homozygous mutation of *EXT1/EXT2* and committed stem cells/wild-type chondrocytes. Osteochondroma serves as a niche (a permissive environment), which facilitates the committed stem cells/wild-type chondrocytes to acquire secondary genetic changes to form a secondary peripheral chondrosarcoma. In such a scenario, the micro-environment is the site of the initiating processes that ultimately lead to cancer.

Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

**Keywords:** growth plate; osteochondroma; gradients; polarity; primary cilia; proteoglycans; bone tumour

Received 10 August 2011; Revised 20 September 2011; Accepted 22 September 2011

No conflicts of interest were declared.


## Introduction

Skeletal development is a highly orchestrated process in which all the players involved ought to be perfectly coordinated and regulated in order to achieve harmonious and symmetrical growth. During mammalian skeletal development, long, short and irregular bones are formed by endochondral ossification [1,2].

Endochondral ossification begins when progenitor chondrocytes derived from mesenchymal cells pack densely (so-called ‘condensation’). Cells of condensation form a cartilaginous template that is ultimately replaced by bone (Figure 1). Cell–cell interactions and the transcription factor Sox9 regulate the formation of these condensations [3]. Cell adhesion molecules, such as N-cadherin and N-CAM, are important in establishing an aggregation centre by recruiting mesenchymal cells from surrounding tissue [2]. Sox9 plays a key role in the differentiation of progenitor chondrocytes into chondrocytes by modulating the expression of cartilage-specific genes, such as type II and type XI collagen genes [3]. Down-regulation of N-CAM by the binding of syndecan to fibronectin and activation of

homeobox genes (ie *Msx-1* and *Msx-2*) by the presence of BMP-2 and BMP-4 stop condensation growth and initiate pre-chondrocyte differentiation (Figure 1) [3]. An abundant cartilaginous extracellular matrix (ECM) surrounds mature chondrocytes. Cell–cell interactions found in the condensations are now replaced by interactions between chondrocytes via their ECM. These interactions are mediated by proteoglycans and have important effects on chondrocyte functions [4,5].

Post-natal endochondral bone formation is found in the epiphyseal growth plate. The epiphyseal growth plate is a highly organized, cartilaginous template needed for the elongation of long bones. Structurally, the epiphyseal growth plate can be divided into three distinct zones [6]. In the resting zone, chondrocytes are non-polarized and irregularly arranged. Resting chondrocytes serve as precursors (committed stem cell pool) for proliferative chondrocytes. In the proliferating zone, cell division of chondrocytes occurs perpendicular to the long axis of the growing bone (Figure 1). Proliferating chondrocytes have to undertake a series of cell movements/rotations (intercalation) and shape changes to align one on top of the other to generate



**Figure 1.** Endochondral bone formation and the epiphyseal growth plate. (A) Mesenchymal cells condense. (B) Cells of condensation become chondrocytes. (C) Several sequences of chondrocytes proliferation and hypertrophy regulated by highly coordinated signalling pathways form cartilage templates for bone formation. (D, E) Cell–matrix interactions, in part mediated by primary cilia, organize the cartilage templates (ie the epiphyseal growth plate); (D) in columns of proliferating and hypertrophic chondrocytes. The hypertrophic chondrocytes are ultimately replaced by bone. Double arrow-bar indicates long axis of the growing bone.

the typical chondrocyte columns of the growth plate (Figure 1) [7–9]. Once acquired, this columnar organization is maintained. Chondrocytes require adhesion to cartilaginous ECM for all types of shape changes. Integrins are an important family of receptors that mediate chondrocyte–matrix adhesion [10]. Integrins regulate centrosome function, the assembly of the mitotic spindle and cytokinesis [11]. In  $\beta 1$ -null growth plates, chondrocytes display mitotic figures perpendicular to the long axis, but they stay side-by-side and failed to move over each other and form columns, suggesting that  $\beta 1$  integrins regulate chondrocyte shape and rotation [12]. In the hypertrophic zone, chondrocytes stop proliferating and change their expression profile to synthesize type X collagen and to prepare for mineralization of the surrounding cartilaginous ECM (Figure 1) [6].

The process of endochondral bone formation in the epiphyseal growth plate may be considered as a patterning process that begins with chondrocytes proliferation and ends with matrix ossification. The endochondral chondrocytes undergo successive sequences of cell division, matrix secretion, cell hypertrophy, apoptosis and matrix calcification/mineralization.

Although many biological processes contribute to the formation and organization of the epiphyseal growth plate and the initiation of tumours related to the growth plate (osteochondromas and secondary peripheral chondrosarcomas), this review focus on how chondrocytes interact with their ECM to establish cell polarity or not, contributing to morphogenesis and, in the case of neoplastic growth, to tumourigenesis.

### Gradients modulating the organization of the epiphyseal growth plate

According to positional information concepts, cells acquire ‘positional values’ in a three-dimensional (3D) coordinate system which are later interpreted as leading to the formation of the appropriated structure at that position [13–15]. ‘Positional values’ are conferred by morphogens [16]. Concentration gradients of morphogens allows for their diffusion into the developing tissue, generating short- and long-range signalling molecules. Subsequently, chondrocytes at different positions along the epiphyseal growth plate

are exposed to different concentrations of morphogens. The transduction of these signalling molecules is crucial for the formation of distinct zones. Each zone has different patterns of proliferation, differentiation and cell morphology.

Several models explain the formation of morphogen gradients, such as passive diffusion, planar transcytosis and others [17]. In planar transcytosis, morphogens move from the source by active transport, through repeated endocytosis and re-secretion [17].

Throughout the ECM, the distribution of morphogens in a gradient fashion is shown to be established by proteoglycans [5,18,19]. Proteoglycans are found in the ECM and attached to the cell membrane in virtually all types of tissue. They are composed of highly diverse core proteins, to which one or more glycosaminoglycans chains are covalently linked. Proteoglycans influence the morphogens-receptor, binding affinity and responses of cells to secreted proteins [4].

Recently, by studying the distribution of the proteoglycans anionic sites, it has been shown that, in zebrafish cartilage and in the human epiphyseal growth plate, proteoglycans are distributed in a gradient fashion [20]. A concentration gradient of proteoglycans in the cartilaginous ECM is observed as a function of the distance from the cell surface. Therefore, proteoglycans regulate the distribution of morphogens across the ECM [17]. Proteoglycans, such as heparan and chondroitin sulphate, function in concert to establish an Indian hedgehog (Ihh) gradient, either through affecting its diffusion or by protecting it from degradation [19]. Ihh is a key regulator of the epiphyseal growth plate. The balance between chondrocyte proliferation and chondrocyte hypertrophy is regulated by a negative feedback loop involving Ihh and parathyroid hormone-related peptide (PTHrP; also known as PTHIH) [21,22]. Ihh is secreted by pre-hypertrophic chondrocytes and diffuses away from its site of synthesis regulating proliferation in a pool of cells that precedes them within the columns of stacked chondrocytes, namely chondrocytes from the resting and proliferating zone [6]. Additionally, Ihh signals to the cells of perichondrium and up-regulates their synthesis of PTHrP. PTHrP diffuses to the pre-hypertrophic zone and signals to the PTH/PTHrP receptor expressed on pre-hypertrophic chondrocytes to suppress their differentiation into hypertrophic chondrocytes [22].

Ihh induces the expression of several bone morphogenetic proteins (BMP) in the flaking perichondrium/periosteum and the proliferating chondrocytes [21]. BMP is a group of proteins within the transforming growth factor- $\beta$  (TGF- $\beta$ ) superfamily. BMP and Ihh signals act in parallel to induce chondrocyte proliferation [21]. Additionally, BMP signalling stimulates expression of Ihh [21,23]. Finally, BMP signals independent of the Ihh/PTHrP pathway delaying the process of hypertrophic differentiation [21].

## The polarization of the epiphyseal growth plate

Cell polarity can be defined as a structurally and functionally asymmetric organization in which the non-random positioning of each organelle, the function of which contributes to cell asymmetry, is preserved and transmitted through cell division [24]. Planar cell polarity coordinates cell behaviour in a two-dimensional (2D) plane. Spatial information that organizes planar polarity and ultimately a tissue is shown to be transmitted locally from one cell to the next [25]. Input from neighbouring cells can influence the behaviour of individual cells as well as the orientation of groups of cells that respond as a unit to 'positional values' [25].

The core planar cell polarity is regulated by Wingless-type (Wnt) molecules that comprise a family of 19 lipid-modified secreted glycoproteins, such as Wnt5A. Wnt molecules are diffusible morphogens, which interact with heparan sulphate proteoglycans to generate a gradient throughout the tissue [26]. By binding to frizzled (Fzd) cell surface receptors, Wnt molecules signal via different pathways, including the canonical Wnt/ $\beta$ -catenin, non-canonical Wnt/ $\text{Ca}^{2+}$  and non-canonical Wnt/planar cell polarity pathways [27,28].

Planar cell polarity pathway has been demonstrated to regulate chondrocyte polarity in the epiphyseal growth plate [9]. Non-polarized resting chondrocytes, which are committed progenitor cells responsible for the generation of proliferating chondrocytes, become polarized proliferating chondrocytes assuming a precise position and orientation in the epiphyseal growth plate, creating columns of stacked cells (Figure 1). Planar cell polarity pathway comprises molecules such as Wnt5A, the Rho family of GTPases and Gpi-anchored proteins. These molecules are shown to regulate orientated cell division and movements (intercalation) of chondrocytes (Figure 1) [7–9].

Vertebrate planar cell polarity has been linked to primary cilia, which are specialized cell surface projections present on most eukaryotic cells [29,30]. The primary cilia function as the signalling 'antennae' of the cells that receives and transduces mechanical and chemical signals from the neighbouring cells and the ECM (Figure 1) [31]. During development, the positioning of the primary cilium of the hair cells in the sensory epithelium leads and predicts the polarity of each stereociliary bundle, supporting the hypothesis that primary cilia direct the polarization of hair cells [32,33].

In the resting growth plate chondrocytes, primary cilia do not acquire a clear pattern of orientation. However, in the proliferating and hypertrophic chondrocytes, primary cilia are orientated parallel to the longitudinal axis of the bone (Figure 1) [34]. The polarization of primary cilia in the proliferating and hypertrophic zones of the epiphyseal growth plate creates a virtual axis that crosses the centre of each column of stacked chondrocytes (Figure 1). The parallel ciliary axes across the epiphyseal growth plate seem to

represent the planar polarity axis of the chondrocyte, and consequently of the entire epiphyseal growth plate [34].

In epithelial cells, the activation Rho GTPase takes place at the primary cilium's basal body [35]. In the mouse growth plate, Rho GTPase has been shown to control tissue polarity [9]. Moreover, conditional deletion of *Kif3a* in the growth plate chondrocytes results in the depletion of cilia and loss of columnar organization [8], suggesting the loss of tissue polarity. *Kif3a*, a subunit of the anterograde kinesin-II intraflagellar transport machinery, is required for the formation of primary cilia [36]. Therefore, primary cilia seem to play a role in the polarization of the epiphyseal growth plate.

Taken together, the lack of cell–cell contact in the epiphyseal growth plate turns cell–matrix interaction critical. In such a scenario, chondrocytes interact with their neighbouring chondrocytes and distant cells. These interactions are shown to be partially mediated by primary cilia that regulate and modulate the functions of the epiphyseal growth plate (Figure 1).

The epiphyseal growth plate's fate is to be resorbed after the pubertal growth spurt, at the time of sexual maturation [37]. The resorption and fusion of the growth plate follow the cessation of growth and are regulated by both systemic mechanisms (ie oestrogen hormone) and local mechanisms, intrinsic to the growth plate [38,39]. It has been described that the growth plate chondrocytes have a finite proliferative capacity [39]. Therefore, the fusion of the growth plate is triggered when the proliferative potential of the chondrocytes is exhausted and finally all the remaining chondrocytes are replaced by bone, in which the epiphysis fuses with the metaphysis [37].

## Osteochondromagenesis

Mutations affecting the biosynthesis of either proteoglycans or glycosaminoglycans alter the interaction between a cell and its micro-environment and are the cause of several human disorders. Several of these disorders are associated with a skeletal and articular phenotype [40].

Mutations in *EXT1* (8q24.1) and *EXT2* (11p11) genes are associated with osteochondromas [41–44]. *EXT1* and *EXT2* encode type II transmembrane glycosyltransferases [45,46], whose functions are not fully known. *EXT1* and *EXT2* form a hetero-oligomeric complex in the Golgi apparatus of most human cells that participate in chain elongation in heparan sulphate biosynthesis [47,48]. Albeit the genetic correlation between mutations in *EXT1/EXT2* and osteochondromas, the mechanism by which alterations in heparan sulphate biosynthesis leads to osteochondroma is not entirely understood. As heparan sulphate acts as a co-receptor for fibroblast growth factors and BMPs [49], and regulates the diffusion of *Ihh* [19] and members of the *Wnt* family [26], improper elongation of heparan

sulphate chains may result in a variety of growth factor signalling defects and impaired cell–matrix interactions, which ultimately may result in osteochondroma formation (Figure 2).


Osteochondromas are the most common benign bone tumours of childhood and adolescence [50]. They are characterized by sporadic (non-familial/solitary) or multiple (hereditary) cartilage-capped bony projections from the metaphyses of endochondral bones adjacent to the growth plate and develop during skeletal growth [51]. Multiple osteochondromas, previously called hereditary multiple exostoses, is an autosomal dominant disorder with a prevalence of 1 in 18 000 [52]. Patients with multiple osteochondromas are often short in stature and have bowed bones that can restrict movement and ultimately result in joint dislocation [52]. In contrast, patients with sporadic lesions may develop symptoms on the affected side only. Sporadic and multiple lesions are morphologically indistinguishable [51,53].

Multiple osteochondromas is characterized by genetic variability, which partially explain inter- and intra-familial phenotypic variation often found in these patients [54]. The majority of the hereditary cases are caused by point mutations (70–75%). Small deletions involving single or multiple exons are found in about 10% of all hereditary cases [55–57]. Large deletions have been identified in few cases [54]. No genomic alterations are detected in about 10–15%. In some of these negative cases, somatic mosaicism with large genomic deletions of *EXT1* and *EXT2* has been described as the underlying mechanism of multiple osteochondromas formation [58]. In sporadic osteochondromas, homozygous deletions of *EXT1* are often identified [42].

## A propitious micro-environment for osteochondromagenesis

Model systems have provided significant insight into osteochondromagenesis. Zebrafish *dackel* (*dak/ext2*) mutant has cartilage defects that strongly resemble those seen in patients with multiple osteochondromas [59]. Interestingly, *dak* chondrocytes (chondrocytes with homozygous mutation in *ext2*) behave as wild-type cells when juxtaposed with heparan sulphate-secreting cells and form osteochondroma-like outgrowths when implanted at the edge of wild-type cartilage [60]. This shows that the secretion of heparan sulphate from the neighbouring wild-type chondrocytes is able to rescue the chondrocytes with homozygous mutation in *ext2*. Only, at the edge of the cartilage elements, where the level of heparan sulphate is decreased, chondrocytes with homozygous mutation in *ext2* are able to form outgrowths [60].

Studies using Cre recombinase drivers to generate *Ext1* knockouts in mouse skeletal cells show that somatic loss of the wild-type *Ext1* allele is needed for



**Figure 2.** Osteochondroma- and secondary peripheral chondrosarcomagenesis. (A) The secretion of heparan sulphate from the neighbouring wild-type growth plate chondrocytes is able to rescue the cells with homozygous inactivation of *EXT1/EXT2* (blue cells). (B) A pool of cells with homozygous inactivation of *EXT1/EXT2* disrupts the diffusion gradients and signal transduction in the epiphyseal growth plate. These cells do not respond to polarity signals, leading to loss of cell/tissue polarity. (C) When located adjacent to the perichondrium (arrow), cells with homozygous inactivation of *EXT1/EXT2* form outgrowths (osteochondroma). (D) The osteochondroma cap is then shaped by wild-type cells (red cells) and/or committed stem cells (white cells) and *EXT1/EXT2* homozygous mutant cells. (E) Secondary peripheral chondrosarcoma originates from *EXT1/EXT2* homozygous mutant cells or wild-type cells or committed stem cells that acquire genetic(s) alteration(s).

osteochondroma formation [61]. Recently, it has been shown that, in humans and in animal models, cells with functional *EXT* are being integrated into the osteochondroma cartilaginous cap [20,34,61,62]. These cells might be wild-type chondrocytes from the epiphyseal growth plate or stem cells from the neighbouring tissue. Recently, a subset of cells in the osteochondroma cap has been shown to express nestin, a protein marker for neural stem cells [63]. Although nestin levels are higher in younger patients, nestin-positive cells are also identified in older adults [63], suggesting the presence of committed stem cells or cells with stem cells properties in the osteochondroma cap. The occurrence of osteochondroma in childhood after haematopoietic stem cell transplantation has been reported in the literature [64]. Osteochondromas after stem cell transplantation are linked to total-body irradiation and their cause is still unclear. They might be the result of a prolonged duration of epiphyseal opening caused by damage to bone and cartilage at the epiphysis [64]. Alternatively, the growth hormone treatment that is often indicated to patients with total-body irradiation and haematopoietic stem cell transplantation [65] may disturb the process of endochondral ossification, triggering the committed stem cells from the epiphyseal growth plate or from the neighbouring tissue to form outgrowths.

The wild-type cells in the osteochondroma cap may create an environment conducive for chondrocytes with homozygous inactivation of *EXT1/EXT2* to proliferate and grow [66], probably providing a certain threshold level and distribution of heparan sulphate proteoglycans.

By studying the distribution of the anionic sites of proteoglycans, it has been shown that the mosaic mixture of wild-type chondrocytes and chondrocytes with homozygous inactivation of *EXT1/EXT2* confers to the osteochondroma cap a scattered distribution of proteoglycans across the ECM [20]. Areas with a growth plate-like distribution of proteoglycans in gradients possibly contain chondrocytes with functional *EXT1/EXT2*. Areas with reduced amount of proteoglycans with no gradient formation have probably chondrocytes with homozygous inactivation of *EXT1/EXT2*. It has been shown that cell polarity is lost in osteochondroma, which is reflected either by the random orientation of primary cilia in the tumour or the lack of these organelles in some osteochondroma cells [34]. Interestingly, the columns of stacked cells in osteochondroma retained the growth plate's cell polarity, in which primary cilia are aligned in a common axis, indicating the presence of wild-type chondrocytes in the tumour [34].

Most likely, the formation of an osteochondroma takes place when epiphyseal growth plate chondrocytes with homozygous inactivation of *EXT1/EXT2* disrupt the diffusion gradients and signal transduction. Cells with homozygous inactivation of *EXT1/EXT2* lose their ability to respond to polarity signals [34]. Hypothetically, shorter heparan sulphate chains disrupt the polarity function of primary cilia in osteochondroma cells, which leads to loss of cell/tissue polarity. If cells with homozygous inactivation of *EXT1/EXT2* are located immediately adjacent to the perichondrium, they are able to escape the proteoglycan gradient generated by

neighbouring wild-type chondrocytes and form outgrowths (Figure 2).

A similar mosaic of cells with functional and dysfunctional *EXT1/EXT2* might be present in the epiphyseal growth plate of patient with multiple osteochondromas. In such a scenario, the orientation of primary cilia in the epiphyseal growth plate of patients with osteochondromas and in the osteochondromas themselves might be similar: polarized in the subset of cells that are organized into columns (wild-type chondrocytes) and non-polarized in the subset of cells that are haphazardly organized (cells with homozygous inactivation of *EXT1/EXT2*). Speculatively, the epiphyseal growth plate of a subset of patients with multiple osteochondromas does not show the typical columns of stacked chondrocytes, which might explain the short stature and the bowed bones often seen in those patients. The lack of availability of epiphyseal growth plate material from those patients does not allow to verify the hypothesis. Interestingly, mice with mutations in genes related to cell polarity processes display epiphyseal growth plates with loss of columnar organization, which decrease longitudinal growth and increase lateral expansion of the bone [9].

In mouse model of hereditary human osteochondromas based on stochastic, tissue-specific inactivation of *Ext1*, it has been demonstrated that osteochondromas develop quickly during the early post-natal period, corresponding to rapid bone growth [62]. Additionally, wild-type cells constitute the major population of cells in the tumour [62]. It indicates that homozygous inactivation of *Ext1* in a small fraction of chondrocytes is required and sufficient for the initiation of osteochondromas in this model. In human osteochondromas, it has been shown by fluorescence *in situ* hybridization (FISH) with an *EXT1* probe that cells with homozygous deletion of *EXT1* constitute the major population of cells in the tumour [67]. It is plausible to foresee that number of wild-type cells in the osteochondroma cap varies depending on the patient's age, decreasing upon osteochondroma maturation. However, the lack of tumour samples from infants with osteochondromas do not allow further verification whether wild-type cells constitute the major population of cells in more immature osteochondromas.

It is unlikely that wild-type cells in the osteochondroma cap are just an incidental component [62]. Hypothetically, variable ratio between wild-type chondrocytes and cells with homozygous inactivation of *EXT1/EXT2* may explain why osteochondromas cease to grow at the time of sexual maturation and eventually are resorbed [68]. This indicates that the epiphyseal growth plate and osteochondroma may share, to some extent, similar hormonal regulation. The resorbed osteochondromas, which are in general small lesions [68], might be composed mainly by wild-type cells intermingled by few cells with homozygous inactivation of *EXT1/EXT2*. Once the fusion of the epiphyseal growth plate begins, the growth of an osteochondroma composed predominantly by wild-type cells decreases.

As in the epiphyseal growth plate, the cartilaginous matrix of osteochondroma might be replaced by bone and, in the absence of a conducive environment produced by the wild-type cells, cells with homozygous inactivation of *EXT1/EXT2* may die and the osteochondroma cap could be finally resorbed. In contrast, the unresorbed osteochondromas might be formed predominately by cells with homozygous inactivation of *EXT1/EXT2*. It is possible to foresee that the high ratio of mutated cells over the non-mutated cells may create an environment that shield osteochondroma from the mechanisms that regulate the epiphyseal growth plate, preventing the wild-type cells that could lead the resorption of the osteochondroma cap from dying.

### Micro-environment promoting and inducing secondary peripheral chondrosarcoma formation

The 'double-edged sword' role of the micro-environment has become more and more prominent in either suppressing or promoting tumour formation [69]. The micro-environment provides signalling to mediate cell proliferation, differentiation and death, regulating tissue architecture and remodelling [70]. The micro-environment is also able to suppress and revert processes that ultimately lead to cancer. Conversely, the micro-environment has also been described to modulate tumour formation, growth and spread. It means that the micro-environment can disrupt tissue homeostasis and promote cancer development. The destabilization of tissue homeostasis has a variety of causes, including the production of toxic substances by the stromal cells and/or other cell types, ie leading to impairment of signalling molecules [70,71].

Recently, it has been described that either benign or malignant tumour cells can create a special micro-environment that might lead to the formation of a new and different tumour type [72]. This model of tumour formation has been called a 'niche-based' model of oncogenesis, in which a change in a specific niche/micro-environmental cell can serve as the primary moment in a multi-step process towards malignancy of a supported, but distinct, cell type. Evidences for niche-induced oncogenesis come from Shwachman–Bodian–Diamond syndrome and secondary peripheral chondrosarcoma.

Shwachman–Diamond syndrome is an autosomal recessive disorder characterized by bone marrow dysfunction, neurocognitive impairment, pancreatic insufficiency and hepatopathy [73]. It is caused by mutations in the Shwachman–Bodian–Diamond syndrome (*SBDS*) gene and is a predisposition for myelodysplastic changes and leukaemia [72–74]. In Shwachman–Diamond syndrome, the haematopoietic progenitor cells with an *SBDS* gene mutation create a permissive micro-environment that may poise wild-type haematopoietic cells for genetic events initiating malignant transformation [74]. This syndrome illustrates the ability of primary alterations in the bone

marrow micro-environment to initiate specific events that lead to secondary genetic alterations in other cells.

The role of the micro-environment in secondary peripheral chondrosarcoma formation has been recently described (Figure 2) [67]. Secondary peripheral chondrosarcoma is a malignant cartilage-producing tumour that arises from the cartilage cap of an osteochondroma [75]. It has been shown that, while homozygous mutations in *EXT1/EXT2* are crucial for the formation of an osteochondroma, genetic alteration(s) in other gene(s) than *EXT1/EXT2* is(are) the causing event(s) of a subset of secondary peripheral chondrosarcoma [67]. Additionally, *IDH1/IDH2* mutations are shown not to be involved in secondary peripheral chondrosarcoma formation [76]. Malignant progression of secondary peripheral chondrosarcomas is characterized by a high percentage of loss of heterozygosity (ie *CDKN2A/p16*, *TP53*, *RBI*) and ploidy ranging from half to twice the normal DNA content [77–79]. It suggests that *p16*, *p53* and *RBI* are involved in neoplastic transformation of an osteochondroma.

The osteochondroma cells with homozygous inactivation of *EXT1/EXT2* are thought to create a permissive micro-environment that facilitates the *EXT* wild-type cells to acquire secondary genetic changes. The *EXT* wild-type cells may be committed stem cells or wild-type chondrocytes. Such a scenario also points to a niche-based model of oncogenesis. It means that a pool of committed stem cells/wild-type chondrocytes might be found in the osteochondroma cap. The stem cells are committed to differentiate into chondrocytes and, once acquiring genetic alterations in other genes than *EXT1/EXT2* and *IDH1/IDH2*, originate chondrosarcomas and not other type of bone tumours. It has been proposed that sarcoma in general is a differentiation disease, caused by mutations hampering terminal differentiation of mesenchymal stem cells [80]. Depending on the lineage and the stage of differentiation at the time of the mutation, sarcomas with variable phenotype and histological grade could be initiated [80]. Gene expression profiles of differentiated chondrosarcoma (ie low-grade chondrosarcomas) share similarities with fully differentiated chondrocytes (ie growth plate chondrocytes and osteochondroma cells), whereas less differentiated chondrosarcomas (ie high-grade chondrosarcomas) show overlap with pre-chondrogenic stages of mesenchymal stem cells [81]. This means that clonal selection occurs during malignant progression from low-grade to high-grade chondrosarcoma and favours expansion of cell clones with gene expression profile similar to those of mesenchymal stem cells. These cell clones with a stem cell-like genotype suggest that the committed stem cells found in the osteochondroma cap or neighbouring tissue are the cells of origin of secondary peripheral chondrosarcomas. These cells then acquire genetic alteration(s) (ie *p16* or *p53* or *RBI* or others) that give them a proliferative advantage, allowing them

to overgrow the osteochondroma cells with homozygous inactivation of *EXT1/EXT2*. Consequently, secondary peripheral chondrosarcomas are presumably a clonal growth of neoplastic cells, while osteochondromas are clonal growth of different cell types (ie committed stem cells/wild-type chondrocytes and cells with homozygous inactivation of *EXT1/EXT2*). Hypothetically, secondary peripheral chondrosarcomas may arise from clonal growth of committed stem cells/wild-type chondrocytes or cells with homozygous inactivation of *EXT1/EXT2* (Figure 2). Osteochondromas cells originating chondrosarcoma is a rare event, based on the fact that very few secondary peripheral chondrosarcomas display homozygous deletion of *EXT1/EXT2* [67].

Neoplastic transformation of an osteochondroma occurs in <1% of patients with sporadic osteochondromas and 1–3% of patients with multiple osteochondromas [75]. Neoplastic transformation usually occurs 20–60 years after the cessation of osteochondroma growth that happens at the time of the fusion of the epiphyseal growth plate at puberty [41]. It is difficult and challenging to address how the osteochondroma cells with homozygous inactivation of *EXT1/EXT2* facilitate secondary genetic changes in *EXT* wild-type cells. Considering that osteochondromas are cartilage-capped bony projections arising on the external surface of bones, it can be speculated that an osteochondroma is constantly exposed to risk of injury and micro-trauma that might lead the committed stem cells/wild-type chondrocytes, either in the tumour or in the neighbouring tissue, to become more prone to acquire genetic alterations. The question why committed stem cells/wild-type chondrocytes and not *EXT*-mutated cells predominantly acquire genetic changes that lead to malignancy is answered by the fact that *EXT1* mutation gives the cells a proliferative disadvantage. The hypothesis that alterations in *EXT* give the cells a proliferative disadvantage comes from a study in multiple myeloma showing that mutation in *EXT1* leads to decreased tumour growth [82], and from the fact that *EXT*-null chondrocytes do not grow *in vitro* [56].

Eventually, secondary peripheral chondrosarcoma can transform into dedifferentiated chondrosarcoma, which consists of two components, a well-differentiated chondrosarcoma juxtaposed to a high-grade undifferentiated (non-cartilaginous) sarcoma [83]. Dedifferentiation might occur through environmental factors and/or when subsequent mutations drive the differentiated chondrosarcoma cells to undergo to an earlier developmental stage. Alternatively, mutated undifferentiated cells located in the chondrosarcoma through asymmetric cell division might give rise to chondrosarcoma cells and to equivalent undifferentiated cells. Genetic alterations in the undifferentiated cells may confer a proliferative advantage, which leads to an undifferentiated sarcoma.

## Conclusion and future perspectives

In the epiphyseal growth plate, in osteochondroma and in secondary peripheral chondrosarcoma, the way that chondrocytes interact with each other and to their micro-environment has gradually been unveiled. In the epiphyseal growth plate, these interactions lead to the formation of a polarized tissue. Cells in the epiphyseal growth plate harbouring homozygous mutations in *EXT1/EXT2* disrupt the diffusion gradients and signal transduction, leading to the loss of cell polarity and contributing to the formation of an osteochondroma. Osteochondroma acts as a niche (a permissive environment), which facilitates the committed stem cells/wild-type chondrocytes located in its cap to acquire secondary genetic changes to form a secondary peripheral chondrosarcoma.

The identification of a committed stem cell pool in the osteochondroma cap and the isolation of these cells might unveil their potential to originate a malignant tumour. Massive sequencing is expected to identify the driving mutation in secondary peripheral chondrosarcoma formation.

## Acknowledgment

This work was supported by the European Network of Excellence EuroBoNeT [<http://www.eurobonet.eu>; Grant No. 018814 (LSHC-CT-2006-018814)].

## Author contributions

CEdeA and PCWH were both involved in writing the paper and had final approval of the submitted and published versions.

## References

- Campbell JT, Kaplan FS. The role of morphogens in endochondral ossification. *Calcif Tissue Int* 1992; **50**: 283–289.
- Mariani FV, Martin GR. Deciphering skeletal patterning: clues from the limb. *Nature* 2003; **423**: 319–325.
- DeLise AM, Fischer L, Tuan RS. Cellular interactions and signaling in cartilage development. *Osteoarthr Cartilage* 2000; **8**: 309–334.
- Hacker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. *Nat Rev Mol Cell Biol* 2005; **6**: 530–541.
- Willems SM, Wiweger M, Frans Graadt van Roggen J, *et al*. Running GAGs: myxoid matrix revisited. What's in it for the pathologist? *Virchows Arch* 2009; **456**: 181–192.
- Kronenberg HM. Developmental regulation of the growth plate. *Nature* 2003; **423**: 332–336.
- Dodds GS. Row formation and other types of arrangement of cartilage cells in endochondral ossification. *Anat Rec* 1930; **46**: 385–399.
- Song B, Haycraft CJ, Seo H, *et al*. Development of the post-natal growth plate requires intraflagellar transport proteins. *Dev Biol* 2007; **305**: 202–216.
- Li Y, Dudley AT. Noncanonical frizzled signaling regulates cell polarity of growth plate chondrocytes. *Development* 2009; **136**: 1083–1092.
- Grashoff C, Aszodi A, Sakai T, *et al*. Integrin-linked kinase regulates chondrocyte shape and proliferation. *EMBO Rep* 2003; **4**: 432–438.
- Reverte CG, Benware A, Jones CW, *et al*. Perturbing integrin function inhibits microtubule growth from centrosomes, spindle assembly, and cytokinesis. *J Cell Biol* 2006; **174**: 491–497.
- Aszodi A, Hunziker EB, Brakebusch C, *et al*.  $\beta 1$  integrins regulate chondrocyte rotation, G<sub>1</sub> progression, and cytokinesis. *Genes Dev* 2003; **17**: 2465–2479.
- Wolpert L. Positional information and pattern formation in development. *Dev Genet* 1994; **15**: 485–490.
- Wolpert L. Positional information revisited. *Development* 1989; **107**(suppl): 3–12.
- Tickle C. Making digit patterns in the vertebrate limb. *Nat Rev Mol Cell Biol* 2006; **7**: 45–53.
- Salinas PC. Signaling at the vertebrate synapse: new roles for embryonic morphogens? *J Neurobiol* 2005; **64**: 435–445.
- Yan D, Lin X. Shaping morphogen gradients by proteoglycans. *Cold Spring Harb Perspect Biol* 2009; **1**: a002493.
- Wu Y, Belenkaya TY, Lin X. Dual roles of *Drosophila* glypican Dally-like in Wingless/Wnt signaling and distribution. *Methods Enzymol* 2010; **480**: 33–50.
- Cortes M, Baria AT, Schwartz NB. Sulfation of chondroitin sulfate proteoglycans is necessary for proper Indian hedgehog signaling in the developing growth plate. *Development* 2009; **136**: 1697–1706.
- de Andrea CE, Prins FA, Wiweger MI, *et al*. Growth plate regulation and osteochondroma formation: insights from tracing proteoglycans in zebrafish models and human cartilage. *J Pathol* 2011; **224**: 160–168.
- Minina E, Wenzel HM, Kreschel C, *et al*. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. *Development* 2001; **128**: 4523–4534.
- Vortkamp A, Lee K, Lanske B, *et al*. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* 1996; **273**: 613–622.
- Zhang D, Schwarz EM, Rosier RN, *et al*. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. *J Bone Miner Res* 2003; **18**: 1593–1604.
- Bornens M. Organelle positioning and cell polarity. *Nat Rev Mol Cell Biol* 2008; **9**: 874–886.
- Jones C, Chen P. Planar cell polarity signaling in vertebrates. *BioEssays* 2007; **29**: 120–132.
- Fuerer C, Habib SJ, Nusse R. A study on the interactions between heparan sulfate proteoglycans and Wnt proteins. *Dev Dyn* 2010; **239**: 184–190.
- Zallen JA. Planar polarity and tissue morphogenesis. *Cell* 2007; **129**: 1051–1063.
- Andersson ER, Prakash N, Cajanek L, *et al*. Wnt5a regulates ventral midbrain morphogenesis and the development of A9–A10 dopaminergic cells *in vivo*. *PLoS ONE* 2008; **3**: e3517.
- Wheatley DN, Feilen EM, Yin Z, *et al*. Primary cilia in cultured mammalian cells: detection with an antibody against deetyrosinated  $\alpha$ -tubulin (ID5) and by electron microscopy. *J Submicrosc Cytol Pathol* 1994; **26**: 91–102.
- Poole CA, Flint MH, Beaumont BW. Analysis of the morphology and function of primary cilia in connective tissues: a cellular cybernetic probe? *Cell Motil* 1995; **5**: 175–193.
- Singla V, Reiter JF. The primary cilium as the cell's antenna: signaling at a sensory organelle. *Science* 2006; **313**: 629–633.
- Denman-Johnson K, Forge A. Establishment of hair bundle polarity and orientation in the developing vestibular system of the mouse. *J Neurocytol* 1999; **28**: 821–835.

33. Tilney LG, Cotanche DA, Tilney MS. Actin filaments, stereocilia and hair cells of the bird cochlea. VI. How the number and arrangement of stereocilia are determined. *Development* 1992; **116**: 213–226.
34. de Andrea CE, Wiweger M, Prins F, *et al.* Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. *Lab Invest* 2010; **90**: 1091–1101.
35. Park TJ, Mitchell BJ, Abitua PB, *et al.* Dishevelled controls apical docking and planar polarization of basal bodies in ciliated epithelial cells. *Nat Genet* 2008; **40**: 871–879.
36. Eggenschwiler JT, Anderson KV. Cilia and developmental signaling. *Annu Rev Cell Dev Biol* 2007; **23**: 345–373.
37. Weise M, De Levi S, Barnes KM, *et al.* Effects of estrogen on growth plate senescence and epiphyseal fusion. *Proc Natl Acad Sci USA* 2001; **98**: 6871–6876.
38. Faustini-Fustini M, Rochira V, Carani C. Oestrogen deficiency in men: where are we today? *Eur J Endocrinol* 1999; **140**: 111–129.
39. Baron J, Klein KO, Colli MJ, *et al.* Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. *Endocrinology* 1994; **135**: 1367–1371.
40. Warman ML, Cormier-Daire V, Hall C, *et al.* Nosology and classification of genetic skeletal disorders: 2010 revision. *Am J Med Genet A* 2011; **155A**: 943–968.
41. Bovee JVMG, Hogendoorn PCW, Wunder JS, *et al.* Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. *Nat Rev Cancer* 2010; **10**: 481–488.
42. Hameetman L, Szuhai K, Yavas A, *et al.* The Role of EXT1 in non hereditary osteochondroma: identification of homozygous deletions. *J Natl Cancer Inst* 2007; **99**: 396–406.
43. Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. *Hum Mutat* 2000; **15**: 220–227.
44. Bovee JVMG, Cleton-Jansen AM, Wuyts W, *et al.* EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. *Am J Hum Genet* 1999; **65**: 689–698.
45. Stickens D, Clines G, Burbee D, *et al.* The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. *Nat Genet* 1996; **14**: 25–32.
46. Ahn J, Ludecke H-J, Lindow S, *et al.* Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). *Nat Genet* 1995; **11**: 137–143.
47. McCormick C, Duncan G, Goutsos KT, *et al.* The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. *Proc Natl Acad Sci USA* 2000; **97**: 668–673.
48. Busse M, Feta A, Presto J, *et al.* Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. *J Biol Chem* 2007; **282**: 32802–32810.
49. Bernfield M, Gotte M, Park PW, *et al.* Functions of cell surface heparan sulfate proteoglycans. *Annu Rev Biochem* 1999; **68**: 729–777.
50. van den Berg H, Kroon HM, Slaar A, *et al.* Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration 'PALGA'. *J Pediatr Orthop* 2008; **28**: 29–35.
51. Khurana J, Abdul-Karim F, Bovee JVMG. Osteochondroma. In *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*, Fletcher CDM, Unni KK, Mertens F (eds). IARC Press: Lyons, France, 2002; 234–236.
52. Stieber JR, Dormans JP. Manifestations of hereditary multiple exostoses. *J Am Acad Orthop Surg* 2005; **13**: 110–120.
53. Romeo S, Hogendoorn PC, Dei Tos AP. Benign cartilaginous tumors of bone: from morphology to somatic and germ-line genetics. *Adv Anat Pathol* 2009; **16**: 307–315.
54. Jennes I, de JD, Mees K, *et al.* Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 multiple osteochondromas families. *BMC Med Genet* 2011; **12**: 85.
55. Hameetman L, David G, Yavas A, *et al.* Decreased EXT expression and intracellular accumulation of HSPG in osteochondromas and peripheral chondrosarcomas. *J Pathol* 2007; **211**: 399–409.
56. Reijnders CM, Waaijer CJ, Hamilton A, *et al.* No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. *Am J Pathol* 2010; **177**: 1946–1957.
57. Zuntini M, Pedrini E, Parra A, *et al.* Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. *Oncogene* 2010; **29**: 3827–3834.
58. Szuhai K, Jennes I, De Jong D, *et al.* Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. *Hum Mutat* 2011; **32**: 2036–2049.
59. Wiweger MI, Avramut CM, de Andrea CE, *et al.* Cartilage ultrastructure in proteoglycan-deficient zebrafish mutants brings to light new candidate genes for human skeletal disorders. *J Pathol* 2011; **223**: 531–542.
60. Clément A, Wiweger M, von der Hardt S, *et al.* Regulation of zebrafish skeletogenesis by *ext2/dackel* and *papst1/pinscher*. *PLoS Genet* 2008; **4**: e1000136.
61. Jones KB, Piombo V, Searby C, *et al.* A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. *Proc Natl Acad Sci USA* 2010; **107**: 2054–2059.
62. Matsumoto K, Irie F, Mackem S, *et al.* A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. *Proc Natl Acad Sci USA* 2010; **107**: 10932–10937.
63. Du K, Peng Y, Zhang L, *et al.* Expression of the stem cell marker nestin in pre/hypertrophic chondrocytes in osteochondroma. *J Int Med Res* 2011; **39**: 348–357.
64. Faraci M, Bagnasco F, Corti P, *et al.* Osteochondroma after hematopoietic stem cell transplantation in childhood. An Italian study on behalf of the AIEOP–HSCT group. *Biol Blood Marrow Transpl* 2009; **15**: 1271–1276.
65. Bordigoni P, Turello R, Clement L, *et al.* Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases. *Bone Marrow Transpl* 2002; **29**: 611–614.
66. Hilton MJ, Gutierrez L, Martinez DA, *et al.* EXT1 regulates chondrocyte proliferation and differentiation during endochondral bone development. *Bone* 2005; **36**: 379–386.
67. de Andrea CE, Reijnders CM, Kroon HM, *et al.* Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. *Oncogene* 2011; DOI: 10.1038/onc.2011.311.
68. Passanise AM, Mehlman CT, Wall EJ, *et al.* Radiographic evidence of regression of a solitary osteochondroma: a report of 4 cases and a literature review. *J Pediatr Orthop* 2011; **31**: 312–316.
69. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. *Nat Med* 2011; **17**: 320–329.
70. Allen M, Louise JJ, Jekyll and Hyde: the role of the microenvironment on the progression of cancer. *J Pathol* 2011; **223**: 162–176.
71. Yen KE, Bittinger MA, Su SM, *et al.* Cancer-associated IDH mutations: biomarker and therapeutic opportunities. *Oncogene* 2010; **29**: 6409–6417.
72. Raaijmakers MH, Mukherjee S, Guo S, *et al.* Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* 2010; **464**: 852–857.

73. Huang JN, Shimamura A. Clinical spectrum and molecular pathophysiology of Shwachman–Diamond syndrome. *Curr Opin Hematol* 2011; **18**: 30–35.
74. Raaijmakers M. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. *Haematologica* 2011; **96**: 1041–1048.
75. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*, Fletcher CDM, Unni KK, Mertens F (eds). IARC Press: Lyons, France, 2002; 247–251.
76. Amary MF, Bacsik K, Maggiani F, *et al.* *IDH1* and *IDH2* mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol* 2011; **224**: 334–343.
77. Hallor KH, Staaf J, Bovée JVMG, *et al.* Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. *Clin Cancer Res* 2009; **15**: 2685–2694.
78. Bovée JVMG, Royen Mv, Bardoel AFJ, *et al.* Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. *Am J Pathol* 2000; **157**: 1587–1595.
79. Bovée JVMG, Sciot R, Dal Cin P, *et al.* Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. *Diagn Mol Pathol* 2001; **10**: 228–236.
80. Mohseny AB, Hogendoorn PCW. Concise review: mesenchymal tumors: when stem cells go mad. *Stem Cells* 2011; **29**: 397–403.
81. Boeuf S, Kunz P, Hennig T, *et al.* A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. *J Pathol* 2008; **216**: 158–166.
82. Reijmers RM, Groen RW, Rozemuller H, *et al.* Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. *Blood* 2010; **115**: 601–604.
83. Rozeman LB, de Bruijn IH, Bacchini P, *et al.* Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. *Mod Pathol* 2009; **22**: 1489–1498.